Treatment challenges associated with breast cancer and chemotherapeutic drug resistance

Abstract

The most frequent form of cancer in women worldwide and the main factor in mortality from cancer, breast cancer is a common malignancy. In 2012, there were 521,900 cancer deaths and an estimated 1.7 million new cases of cancer (or 25% of all cancer kinds). Women are at risk for breast cancer for a variety of reasons, but breast density, genetic predisposition, age, and estrogen dysregulation stand out. A heterogeneous illness like breast cancer is brought on by shared ecological and hereditary factors. Development of novel molecularly targeted therapeutics is facilitated by a thorough understanding of the genesis of breast cancer. Numerous variables, including tumor size, lymph node involvement, and the presence of estrogen, progesterone, and HER2 receptors, determine the therapeutic efficacy of chemotherapy. One of the main issues with cancer chemotherapy, particularly in the case of breast tumors, is drug resistance. In order to achieve this, a number of active trials are investigating brand-new medication combinations that aim to block important signaling pathways that contribute to the development of disease. These therapeutic advancements may help individuals with breast cancer overcome their treatment resistance. Additionally, finding additional biomarkers and possible drug targets may help to create new chemotherapeutic combinations that eventually increase the effectiveness of these combination therapies.